MedPath

Evaluation of the effect of Microrelin in treatment of metastatic prostate cancer

Phase 1
Conditions
Prostate Cancer.
Malignant neoplasm of prostate
Registration Number
IRCT201310229819N3
Lead Sponsor
Vice chancellor for research Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Male
Target Recruitment
40
Inclusion Criteria

All patients with metastatic prostate cancer without age limitation who are referred to urology clinic of Imam Khomeyni Hospital in 01.21.2014 until 01.21.2015 and accepted the term and condition of this study.
Exclusion criteria: Reluctance of patients to continue the study or in case of death

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
PSA. Timepoint: Before intervention, one month after intervention, three months after intervention and six months after intervention. Method of measurement: ELIZA.;Serum Testosterone. Timepoint: Before intervention, one month after intervention, three months after intervention and six months after intervention. Method of measurement: ELIZA.
Secondary Outcome Measures
NameTimeMethod
oss of libido (Sexual desire was absent in all cases following castration) and Hot flash (As a subjective feeling of warmth in the head followed by objective perspiration, hot flashes are not life threatening but are among the most common side effects of androgen ablation). Timepoint: At every visit. Method of measurement: With history taking and physical exam.
© Copyright 2025. All Rights Reserved by MedPath